Overview A Study of GenSci098 in Subjects With Active Thyroid Eye Disease Status: RECRUITING Trial end date: 2027-12-13 Target enrollment: Participant gender: Summary To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)Phase: PHASE1 Details Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.